Patents by Inventor Staffan Skogvall
Staffan Skogvall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200140287Abstract: A method and a system for isolating potentially harmful medical substances, such as antibiotics, is disclosed. Blackwater ejected from vacuum toilets contains potentially harmful medical substances present in dissolved state in bodily waste. The ejected blackwater is subjected to an initial treatment including a bacteria reduction and a fragmentation for producing an initially treated blackwater slurry. The blackwater slurry is transferred via one or more buffer tanks to a central vaporization unit in which water is vaporized from the blackwater slurry for producing a water-reduced waste material containing said potentially harmful medical substances. The waste material is transferred into one or more replaceable waste containers. The waste material may be subjected to a further water reduction, optionally before the waste containers are removed.Type: ApplicationFiled: April 27, 2018Publication date: May 7, 2020Inventor: Staffan SKOGVALL
-
Publication number: 20200131050Abstract: A method and an apparatus for isolating potentially harmful medical substances, such as antibiotics, is disclosed. An aqueous composition, such as blackwater, contains potentially harmful medical substances present in dissolved state in bodily waste. The aqueous composition is temporarily stored in a buffer tank and is then transferred in batches to a vaporization unit comprising one or more vaporization chambers for producing a water-reduced waste material containing said potentially harmful medical substances. The waste material is subjected to a destructive treatment, such as a high-temperature incineration process.Type: ApplicationFiled: April 28, 2017Publication date: April 30, 2020Inventor: Staffan SKOGVALL
-
Patent number: 10626023Abstract: There is disclosed a method and an apparatus for reducing the amount of waste, requiring special handling and possible destruction, in a process involving vaporization, in an evaporator apparatus (1-6, V1-V6), of a water solution containing environmentally hazardous substances. A considerable amount of the water content of said water solution is vaporized in a reusable vaporization chamber (2a). At a certain time, the vaporization process is stopped, so that the remaining water content is 70% to 5% of the initial water content. Thereafter, in a second step, the remaining water solution in the reusable vaporization chamber (2a) is transferred into a separate waste isolating container (6), where the remaining water is subjected to at least one further water-reducing process. The remaining waste, including the environmentally hazardous substances, is left in the waste container for separate handling and possible destruction.Type: GrantFiled: November 1, 2016Date of Patent: April 21, 2020Assignee: Pharmalundensis ABInventor: Staffan Skogvall
-
Publication number: 20180327277Abstract: There is disclosed a method and an apparatus for reducing the amount of waste, requiring special handling and possible destruction, in a process involving vaporization, in an evaporator apparatus (1-6, V1-V6), of a water solution containing environmentally hazardous substances. A considerable amount of the water content of said water solution is vaporized in a reusable vaporization chamber (2a). At a certain time, the vaporization process is stopped, so that the remaining water content is 70% to 5% of the initial water content. Thereafter, in a second step, the remaining water solution in the reusable vaporization chamber (2a) is transferred into a separate waste isolating container (6), where the remaining water is subjected to at least one further water-reducing process. The remaining waste, including the environmentally hazardous substances, is left in the waste container for separate handling and possible destruction.Type: ApplicationFiled: November 1, 2016Publication date: November 15, 2018Applicant: Pharmalundensis ABInventor: Staffan Skogvall
-
Publication number: 20180200292Abstract: A pharmaceutical composition for obtaining an improved lung function in a human or an animal lung affected by airway obstruction such as COPD or asthma, is provided. The composition comprises a pharmacologically effective amount of activated carbon comprising adsorbed iodine and/or an adsorbed iodide salt and a sodium/iodide symporter inhibitor, such as perchlorate. Additionally, a method for obtaining an improved lung function in a human or animal lung affected by airway obstruction, such as COPD or asthma, is provided. The method comprises the steps of administering a pharmacologically effective amount of activated carbon comprising adsorbed iodine and/or an adsorbed iodide salt, and administering a sodium/iodide symporter inhibitor, such as perchlorate, in connection to the administration of the pharmacologically effective amount of activated carbon comprising adsorbed iodine and/or an adsorbed iodide salt.Type: ApplicationFiled: March 7, 2018Publication date: July 19, 2018Inventor: Staffan Skogvall
-
Patent number: 9943542Abstract: A pharmaceutical composition for obtaining an improved lung function in a human or an animal lung affected by airway obstruction such as COPD or asthma, is provided. The composition comprises a pharmacologically effective amount of activated carbon comprising adsorbed iodine and/or an adsorbed iodide salt and a sodium/iodide symporter inhibitor, such as perchlorate. Additionally, a method for obtaining an improved lung function in a human or animal lung affected by airway obstruction, such as COPD or asthma, is provided. The method comprises the steps of administering a pharmacologically effective amount of activated carbon comprising adsorbed iodine and/or an adsorbed iodide salt, and administering a sodium/iodide symporter inhibitor, such as perchlorate, in connection to the administration of the pharmacologically effective amount of activated carbon comprising adsorbed iodine and/or an adsorbed iodide salt.Type: GrantFiled: November 20, 2014Date of Patent: April 17, 2018Assignee: PHARMALUNDENSIS ABInventor: Staffan Skogvall
-
Publication number: 20160271170Abstract: A pharmaceutical composition for obtaining an improved lung function in a human or an animal lung affected by airway obstruction such as COPD or asthma, is provided. The composition comprises a pharmacologically effective amount of activated carbon comprising adsorbed iodine and/or an adsorbed iodide salt and a sodium/iodide symporter inhibitor, such as perchlorate. Additionally, a method for obtaining an improved lung function in a human or animal lung affected by airway obstruction, such as COPD or asthma, is provided. The method comprises the steps of administering a pharmacologically effective amount of activated carbon comprising adsorbed iodine and/or an adsorbed iodide salt, and administering a sodium/iodide symporter inhibitor, such as perchlorate, in connection to the administration of the pharmacologically effective amount of activated carbon comprising adsorbed iodine and/or an adsorbed iodide salt.Type: ApplicationFiled: November 20, 2014Publication date: September 22, 2016Inventor: Staffan Skogvall
-
Publication number: 20150297637Abstract: The present invention provides activated carbon comprising an adsorbed iodide salt selected from the group of alkali metal iodides and earth alkali iodides, for use in a method for treating chronic bronchitis.Type: ApplicationFiled: November 28, 2012Publication date: October 22, 2015Inventor: Staffan Skogvall
-
Publication number: 20130209581Abstract: The present invention relates to the use of iodinated activated charcoal, optionally in combination with a bromide salt, in treatment of one or more symptom(s) caused by depression, wherein said symptom(s) is/are selected from the group consisting depressive mood, emotional fatigue, mental fatigue which can be chronic, burnout, withdrawal from social situations, anxiety, concentration problems, unpleasant heart palpitations, irregular heart beats, a feeling of pressure in the chest, irritable bowel syndrome and sexual dysfunction.Type: ApplicationFiled: June 21, 2011Publication date: August 15, 2013Applicant: PHARMALUNDENSIS ABInventor: Staffan Skogvall
-
Publication number: 20100272814Abstract: A method of producing bronchorelaxation in the lungs of a human or animal affected by airway obstruction comprises administration of a pharmacologically effective amount to the body or to the intestine of said human or animal of an agent capable of binding mercury in elemental, ionic and/or organic form present in the body or in the intestinal lumen to enhance its excretion via the feces and/or the urine. A corresponding use of the agent and its use for the manufacture of a medicament are also disclosed.Type: ApplicationFiled: December 15, 2008Publication date: October 28, 2010Applicant: Pharmalundensis ABInventor: Staffan Skogvall
-
Publication number: 20100266573Abstract: A method for producing bronchorelaxation in a human or an animal affected by airway obstruction comprises administration of a pharmacologically effective amount of elemental iodine on activated charcoal (iodinated activated charcoal) to the intestine of said human or animal. A pharmaceutical composition comprising elemental iodine on activated charcoal and uses thereof is also disclosed.Type: ApplicationFiled: November 18, 2008Publication date: October 21, 2010Applicant: Pharmalundensis ABInventor: Staffan Skogvall
-
Publication number: 20060040919Abstract: A compound of the general formula (I) including its pharmaceutically acceptable acid addition salts wherein A is CHR9, wherein R9 is H, C1-C6 alkyl; n is 1-3; B is CHR10, wherein R10 is H, C1-C6 alkyl; m is 1 or 2; D is O or S; E is CR11R12 or NR13, wherein R11 and R12 are, independent of each other, H or C1-C6 alkyl, R13 is H or C1-C6 alkyl; F is C1-C18 alkyl or R4-R7 cycloalkyl, which may be mono- or di-unsaturated and/or substituted, is useful in treating and preventing pulmonary disease characterized by bronchoconstriction; also disclosed is a pharmaceutical composition comprising the compound of formula (I), a pharmaceutical carrier and, optionally, an anti-asthmatic, a method for its manufacture, and a method for treating or preventing such disease.Type: ApplicationFiled: July 22, 2005Publication date: February 23, 2006Inventors: Staffan Skogvall, Henrik Bjork, Per Berglund, Maria Dalence Guzman, Olov Sterner
-
Publication number: 20060040254Abstract: In a method of measuring a relaxing effect on constricted human bronchi of a candidate substance a bronchus tissue preparation is mounted to a force transducer in a test apparatus. After conditioning the preparation is exposed for a contraction-effective dose of a known contraction-effective substance to make it assume a first tensioned state. The preparation is then exposed for a dose of the candidate substance to make it assume a second tensioned state. By comparing the contraction forces recorded for said tensioned states, a measure of the bronchorelaxing efficiency of the candidate substance is obtained. Also disclosed is a candidate substance thus identified, its uses, and a corresponding bronchus tissue preparation.Type: ApplicationFiled: July 22, 2005Publication date: February 23, 2006Inventor: Staffan Skogvall
-
Publication number: 20050165004Abstract: A compound of the general formula (I) including its pharmaceutically acceptable acid addition salts wherein A is CHR9, wherein R9 is H, C1-C6 alkyl; n is 1-3; B is CHR10, wherein R10 is H, C1-C6 alkyl; m is 1 or 2; D is O or S or optionally NR16, wherein R16 is H, C1-C6 alkyl or C2-C6 acyl; E is CR11R12 or NR13, wherein R11 and R12 are, independent of each other, H or C1-C6 alkyl, R13 is H or C1-C6 alkyl; F is C1-C18 alkyl which may be mono- or di-unsaturated and/or substituted, is useful in treating and preventing pulmonary disease characterized by bronchoconstriction. Also disclosed are pharmaceutical compositions comprising the compound and methods for their manufacture.Type: ApplicationFiled: January 22, 2004Publication date: July 28, 2005Inventors: Staffan Skogvall, Henrik Bjork, Per Berglund, Maria Dalence Guzman, Olov Sterner
-
Publication number: 20050163712Abstract: In a method of measuring a relaxing effect on constricted human bronchi of a candidate substance a bronchus tissue preparation is mounted to a force transducer in a test apparatus. After conditioning the preparation is exposed for a contraction-effective dose of a known contraction-effective substance to make it assume a first tensioned state. The preparation is then exposed for a dose of the candidate substance to make it assume a second tensioned state. By comparing the contraction forces recorded for said tensioned states, a measure of the bronchorelaxing efficiency of the candidate substance is obtained. Also disclosed is a candidate substance thus identified, its uses, and a corresponding bronchus tissue preparation.Type: ApplicationFiled: January 22, 2004Publication date: July 28, 2005Inventors: Staffan Skogvall, Henrik Bjork, Per Magnus Berglund, Maria Fanny Dalence Guzman, Olov Sterner
-
Publication number: 20020173505Abstract: A compound having agonist activity to the 5-HT4 receptor for use as a medicament and the use of said compound in the manufacture of a medicament for use in therapeutic or prophylactic treatment of disorders involving bronchocontraction of a human or animal body is described, as well as methods of treatment, wherein said compounds are administered. Further, a compound having antagonist activity to the 5-HT2a receptor for use as a medicament and the use of said compound in the manufacture of a medicament for use in therapeutic or prophylactic treatment or disorders involving bronchocontraction of a human or animal body is described, as well as methods of treatment, wherein said compounds are administered.Type: ApplicationFiled: October 29, 2001Publication date: November 21, 2002Inventor: Staffan Skogvall